Proteinuria Contributes to Greater CKD Progression Risk in Men
|
By LabMedica International staff writers Posted on 29 Aug 2019 |

Image: A photomicrograph showing numerous completely sclerotic glomeruli and severe chronic tubulointerstitial nephritis from a patient with end-stage kidney disease (Photo courtesy of Dr. Jian-Hua Qiao, MD, FCAP).
Older men with chronic kidney disease had a 50% increased risk for progression to end-stage kidney disease (ESKD) compared with women and this may be the result of higher levels of proteinuria.
End stage kidney disease is the last stage (stage five) of chronic kidney disease (CKD). This means kidneys are only functioning at 10% to 15% of their normal capacity. When kidney function is this low, they cannot effectively remove waste or excess fluid from the blood.
A team of scientists working with the University of Campania (Naples, Italy) evaluated the impact of gender on CKD progression, and conducted a pooled analysis of four observational cohort studies, which included a total of 2,335 men and women with an eGFR of less than 45 mL/min/1.73m2 (mean age, 67.1 years; mean eGFR, 26.9 mL/min/1.73m2). While age, systolic blood pressure and use of renin-angiotensin system inhibitors were similar between men and women, women had a lower median proteinuria (protein excretion, 0.45 g/d) compared with men (0.69 g/d).
The team reported that during a median follow-up of 4.2 years, 757 developed ESKD (59.4% men) and 471 died (58.4% men). The adjusted risks for ESKD and mortality were higher in men (Hazard Ratios (HRs) of 1.50 and 1.30 respectively). This finding was consistent across CKD stages. They observed a significant interaction between gender and proteinuria, with the risk for ESKD in men being significantly greater than for women at a level of proteinuria of ∼0.5 g/d or greater. When examining eGFR, they concluded that the slope of decline in eGFR was steeper in men than in women and that the difference in slopes between men and women was progressively larger with proteinuria less than 0.50 g/d.
The team concluded that data obtained from patients with clinical features consistent with the epidemiologic pattern of the present CKD population worldwide, namely advanced age and high prevalence of diabetes and cardiovascular disease. Still, although their study had some limitations, the results derive from a population of referred white patients with CKD and therefore findings may not hold true for other ethnic groups. Despite this limitation, proteinuria levels may modify the association between sex and renal risk.
Roberto Minutolo, MD, PhD, a Professor of Nephrology, and lead author of the study said, “The importance of sexual dimorphisms has been observed for hypertension and cardiovascular complications with regard to disease presentation, likelihood of progression to advanced phases and response to treatment. To date, the impact of sex on CKD remains poorly defined. In this setting, the mechanisms underlying the observed sex disparity in the epidemiology of kidney diseases have not been fully elucidated.” The study was published on August 10, 2019, in the American Journal of Kidney Diseases.
Related Links:
University of Campania
End stage kidney disease is the last stage (stage five) of chronic kidney disease (CKD). This means kidneys are only functioning at 10% to 15% of their normal capacity. When kidney function is this low, they cannot effectively remove waste or excess fluid from the blood.
A team of scientists working with the University of Campania (Naples, Italy) evaluated the impact of gender on CKD progression, and conducted a pooled analysis of four observational cohort studies, which included a total of 2,335 men and women with an eGFR of less than 45 mL/min/1.73m2 (mean age, 67.1 years; mean eGFR, 26.9 mL/min/1.73m2). While age, systolic blood pressure and use of renin-angiotensin system inhibitors were similar between men and women, women had a lower median proteinuria (protein excretion, 0.45 g/d) compared with men (0.69 g/d).
The team reported that during a median follow-up of 4.2 years, 757 developed ESKD (59.4% men) and 471 died (58.4% men). The adjusted risks for ESKD and mortality were higher in men (Hazard Ratios (HRs) of 1.50 and 1.30 respectively). This finding was consistent across CKD stages. They observed a significant interaction between gender and proteinuria, with the risk for ESKD in men being significantly greater than for women at a level of proteinuria of ∼0.5 g/d or greater. When examining eGFR, they concluded that the slope of decline in eGFR was steeper in men than in women and that the difference in slopes between men and women was progressively larger with proteinuria less than 0.50 g/d.
The team concluded that data obtained from patients with clinical features consistent with the epidemiologic pattern of the present CKD population worldwide, namely advanced age and high prevalence of diabetes and cardiovascular disease. Still, although their study had some limitations, the results derive from a population of referred white patients with CKD and therefore findings may not hold true for other ethnic groups. Despite this limitation, proteinuria levels may modify the association between sex and renal risk.
Roberto Minutolo, MD, PhD, a Professor of Nephrology, and lead author of the study said, “The importance of sexual dimorphisms has been observed for hypertension and cardiovascular complications with regard to disease presentation, likelihood of progression to advanced phases and response to treatment. To date, the impact of sex on CKD remains poorly defined. In this setting, the mechanisms underlying the observed sex disparity in the epidemiology of kidney diseases have not been fully elucidated.” The study was published on August 10, 2019, in the American Journal of Kidney Diseases.
Related Links:
University of Campania
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







